HEALTH

Carter-Wallace to Discontinue Drug: The New York-based maker of pharmaceuticals and toiletries, complying with a government order, said it will stop selling Organidin, which is designed to clear phlegm from the lungs of people with breathing disorders such as bronchitis and asthma. The move was made because of Food and Drug Administration concerns that the drug causes cancer and does not work. The company said it would take a “material” charge in its fiscal 1995 first quarter ending this month to stop shipping the drug. Organidin generated 85% of the company’s earnings before taxes and accounting changes in fiscal 1994. Carter-Wallace warned investors in a Securities and Exchange Commission filing this year that it might have to pull Organidin from the market. Carter-Wallace shares, which have lost about a third of their value in the past month, closed at $16.50, down 87.5 cents, on the NYSE.